The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data
Abstract
BACKGROUND The benefits and risks of testosterone treatment for women with diminished sexual wellbeing remain controversial. We did a systematic review and meta-analysis to assess potential benefits and risks of testosterone for women. METHODS We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for blinded, randomised controlled trials of testosterone treatment of at least 12 weeks' duration completed between Jan 1, 1990, and Dec 10, 2018. We also searched drug registration applications to the European Medicine Agency and the US Food and Drug Administration to identify any unpublished data. Primary outcomes were the effects of testosterone on sexual function, cardiometabolic variables, cognitive measures, and musculoskeletal health. This study is registered with the International Prospective Register of Systematic Reviews (PROSPERO), number CRD42018104073. FINDINGS Our search strategy retrieved 46 reports of 36 randomised controlled trials comprising 8480 participants. Our meta-analysis showed that, compared with placebo or a comparator (eg, oestrogen, with or without progestogen), testosterone significantly increased sexual function, including satisfactory sexual event frequency (mean difference 0·85, 95% CI 0·52 to 1·18), sexual desire (standardised mean difference 0·36, 95% CI 0·22 to 0·50), pleasure (mean difference 6·86, 95% CI 5·19 to 8·52), arousal (standardised mean difference 0·28, 95% CI 0·21 to 0·35), orgasm (standard…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Testosterone therapy, in doses that approximate physiological testosterone concentrations for premenopausal women, exerts a beneficial effect on sexual function including increases, above the effects of placebo/comparator therapy, of an average of one satisfying sexual event per month, and increases in the subdomains of sexual desire, arousal, orgasmic function, pleasure and sexual responsiveness,”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [1]
In the citing paper
“Testosterone therapy, in doses that approximate physiological testosterone concentrations for premenopausal women, exerts a beneficial effect on sexual function including increases, above the effects of placebo/comparator therapy, of an average of one satisfying sexual event per month, and increases in the subdomains of sexual desire, arousal, orgasmic function, pleasure and sexual responsiveness,”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [1]
In the citing paper
“Testosterone therapy, in doses that approximate physiological testosterone concentrations for premenopausal women, exerts a beneficial effect on sexual function including increases, above the effects of placebo/comparator therapy, of an average of one satisfying sexual event per month, and increases in the subdomains of sexual desire, arousal, orgasmic function, pleasure and sexual responsiveness,”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [1]
In the citing paper
“together with a reduction in sexual concerns including sexual distress (Level I, Grade A).”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [1]
In the citing paper
“Recommendations regarding the benefits and risks of testosterone therapy are based on findings from blinded placebo/comparator RCTs, of at least 12 weeks' duration for which data were available for inclusion in meta-analyses 1 .”
From Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) · cites this paper as [1]
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Rosen, C. B. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278597 · Cited by 6,593
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
Davis, S. R., McCloud, P., Strauss, B. J. G., & Burger, H. (1995) · Maturitas · doi:10.1016/0378-5122(94)00898-h · Cited by 533
Self-citationTestosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
Davis, S. R., Moreau, M., Kroll, R., Bouchard, C., Panay, N., Gass, M., Braunstein, G. D., Hirschberg, A. L., Rodenberg, C., Pack, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707302 · Cited by 479
Self-citation
Research works printed but not linked: 2
- Worboys, 2001, Parental testosterone improves endothelium-dependent and independent vasodilation in postmenopausal women already receiving estrogen, J Clin Endocrinol Metab, 86, 158, 10.1210/jcem.86.1.7103 · doi:10.1210/jcem.86.1.7103 · Paper page
- Snabes, 2012, Libigel does not differentiate from placebo therapy in the treatment of hypoactive sexual desire in postmenopausal women, J Sex Med, 9, 171
Cited by
Premature ovarian insufficiency: an international menopause society white paper
Panay, N., Anderson, R. A., Nappi, R. E., Vincent, A. J., Vujovic, S., Webber, L., & Wolfman, W. (2020) · Climacteric · doi:10.1080/13697137.2020.1804547 · Cited by 297
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01603 · Cited by 270
Self-citationMenopause—Biology, consequences, supportive care, and therapeutic options
Davis, S. R., Pinkerton, J., Santoro, N., & Simoncini, T. (2023) · Cell · doi:10.1016/j.cell.2023.08.016 · Cited by 233
Self-citationHamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
“Recent systematic reviews and meta-analyses by Achilli et al. (2017) and Islam et al. (2019) have shown that androgenic side-effects and risks are minimal and reversible if testosterone levels are maintained within the female physiological range.”
BackgroundScavello, I., Maseroli, E., Di Stasi, V., & Vignozzi, L. (2019) · Medicina · doi:10.3390/medicina55090559 · Cited by 184
“It has to be noted that testosterone is not only “the hormone of sex drive and libido”, but it is also considered important for women’s physical and mental wellbeing [63].”
Background
Metadata
- Authors
- Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R.
- Affiliations
- Monash University (AU)
- Corresponding author
- Davis, Susan R
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 7
- Issue
- 10
- Pages
- 754-766
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2963515211
- Cited by
- 278
- References
- 65
- Citations by year
- 2026: 46 · 2025: 52 · 2024: 35 · 2023: 34 · 2022: 38 · 2021: 40 · 2020: 26 · 2019: 7
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (grant (no 1152778))
- NHMRC (no 1135843)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, women, sexual function, postmenopausal women, sexual desire, sexual arousal, orgasm, self-image, cardiometabolic effects, LDL cholesterol, triglycerides, HDL cholesterol, blood pressure, cognitive function, musculoskeletal health, oestrogen-progestogen combination, treatment efficacy and safety, menopause
- MeSH terms
- Androgens, Female, Humans, Libido, Sexual Dysfunction, Physiological, Testosterone, Women's Health, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30189-5
- The paper
- Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30189-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.